GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Cyclically Adjusted FCF per Share

Vertex Pharmaceuticals (BSP:VRTX34) Cyclically Adjusted FCF per Share : R$7.67 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2023 was R$0.557. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$7.67 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 31.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 43.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Vertex Pharmaceuticals was 103.40% per year. The lowest was -23.40% per year. And the median was -5.60% per year.

As of today (2024-04-28), Vertex Pharmaceuticals's current stock price is R$509.49. Vertex Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was R$7.67. Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 66.43.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Vertex Pharmaceuticals was 924.70. The lowest was 55.85. And the median was 72.91.


Vertex Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 2.74 4.52 6.35 7.67

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.35 6.64 6.90 7.89 7.67

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Vertex Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.557/129.4194*129.4194
=0.557

Current CPI (Dec. 2023) = 129.4194.

Vertex Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.477 99.695 -0.619
201406 -0.334 100.560 -0.430
201409 -0.240 100.428 -0.309
201412 -0.544 99.070 -0.711
201503 -0.763 99.621 -0.991
201506 -0.400 100.684 -0.514
201509 -0.286 100.392 -0.369
201512 0.066 99.792 0.086
201603 -0.103 100.470 -0.133
201606 0.087 101.688 0.111
201609 0.172 101.861 0.219
201612 0.444 101.863 0.564
201703 0.800 102.862 1.007
201706 0.538 103.349 0.674
201709 -0.056 104.136 -0.070
201712 0.592 104.011 0.737
201803 0.708 105.290 0.870
201806 1.065 106.317 1.296
201809 1.425 106.507 1.732
201812 1.117 105.998 1.364
201903 1.132 107.251 1.366
201906 1.660 108.070 1.988
201909 1.228 108.329 1.467
201912 1.680 108.420 2.005
202003 3.691 108.902 4.386
202006 5.026 108.767 5.980
202009 3.747 109.815 4.416
202012 2.183 109.897 2.571
202103 4.573 111.754 5.296
202106 -1.202 114.631 -1.357
202109 4.446 115.734 4.972
202112 5.135 117.630 5.650
202203 4.306 121.301 4.594
202206 5.300 125.017 5.487
202209 4.553 125.227 4.705
202212 5.264 125.222 5.440
202303 4.291 127.348 4.361
202306 5.008 128.729 5.035
202309 5.817 129.860 5.797
202312 0.557 129.419 0.557

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Vertex Pharmaceuticals  (BSP:VRTX34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=509.49/7.67
=66.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Vertex Pharmaceuticals was 924.70. The lowest was 55.85. And the median was 72.91.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vertex Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines